At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 14 enrolled
Drug / intervention
Gefitinibdrug
Likely dose
Gefitinib 250 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multicenter Open-label, Long-term Safety Trial of Treatment Extension With ZD1839 in Patients Who Have Been Treated in Other ZD1839 Clinical Trials.
In Brief
A Phase 3 clinical trial evaluating Gefitinib for Lung Cancer and Breast Cancer. Completed, enrolled 14 participants across 7 sites.
Detailed Summary
The purpose of this study is to assess the long-term safety profile and the secondary objective to estimate clinical benefit of ZD1839 (gefitinib).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer, Breast Cancer
CountriesGermany
Collaborators--
Timeline
Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2005
First PostedJul 2006
Primary CompletionMay 2015
TodayJul 2026
First PostedJul 27, 2006
Enrollment StartJan 1, 2005
Primary CompletionMay 1, 2015
TodayJul 2, 2026
Enrollment to primary: 10.3 yearsPosted 19.9 years ago
Interventions
Gefitinibdrug
ZD1839 at a daily dose of 250 mg or 500 mg depending on final dose in parent trial